Breakthrough T1D is proud to host an event celebrating bold innovation in Type 1 Diabetes research. Startups and early-stage companies aligned with our Disease Modifying Therapies and Cell Therapies strategies will showcase their work in areas such as immune modulation, beta cell protection and regeneration, and advanced cell therapy solutions. Breakthrough T1D’s overall goal is to deliver therapies that prevent the onset of Type 1 Diabetes and restore pre-diabetes physiology in people with established Type 1 Diabetes, and this event highlights the advancements bringing us closer to that vision. 

BT1D is excited to award two Golden Tickets, each providing lab space, mentorship, and resources to accelerate the science of two companies at LabCentral. Attendees will have the opportunity to hear from experts, learn more about the future of Type 1 Diabetes therapies, and connect with leaders across biotech, venture, and research. Join us for an inspiring evening dedicated to advancing the next generation of breakthroughs for people living with Type 1 Diabetes

4:00 PM – 4:30 PM: Registration & Networking 
4:30 PM – 4:40 PM: Welcome Remarks from BT1D & LabCentral
4:40 PM – 5:05 PM: IDDP Panel
5:05 PM – 5:45 PM: Finalist Pitches
5:45 PM – 6:00 PM: Judges Deliberation & Networking
6:00 PM – 6:05 PM: Winners Announced
6:05 PM – 7:00 PM: Networking

Arpelos Biosciences, founded by leading antibody engineers and T cell biologists, is advancing a pipeline of targeted, multivalent biologics. Our lead program depletes key pathogenic T cell states to deliver deep, durable responses in inflammatory diseases.

Tezcat Biosciences is an early-stage biotechnology company focused on developing innovative therapeutics to treat recalcitrant diseases. In addition to its oncology pipeline, Tezcat is exploring the utility of a novel protein-drug conjugate carrying an anti-inflammatory agent to innate immune cells for the treatment of Type 1 Diabetes.

Riboway Therapeutics is Boston-based therapeutics company pioneering RNA-targeted therapeutics by decoding hidden layers of RNA regulation to precisely control protein expression—upregulation, downregulation, activation, or inhibition—using an AI-enabled discovery platform. Our proprietary platform identifies target-specific RNA regulatory mechanisms and designs antisense oligonucleotides (ASOs) with validated chemistry to modulate them. This allows us to drug previously inaccessible targets and unlock novel therapeutic mechanisms with precision—validated across 5 out of 5 targets to date. We are building a pipeline in neurodegenerative, autoimmune, and metabolic diseases. 

POLBIONICA has 13 years of experience in bioprinting. We've bioprinted a pancreas, successfully transplanted it in small and large animals and are approaching first in the world transplantation of bioprinted pancreas in humans. We are also bioprinting organoids for drug discovery, cytotoxicity research, and assessment of personalized oncology therapies. 

Full Circles Aims to Develop Life-Saving Genomic Medicine for Autoimmune Disease including T1D and Oncology with Non-Viral C4DNA Cargo Payload - Full Circles Therapeutics aims to revolutionize the treatment of autoimmune diseases through the development of a novel, non-viral in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy utilizing C4DNA, a miniaturized circular single-stranded DNA platform. 

Sanjoy Dutta 

Chief Scientific Officer, Breakthrough T1D

Alan Chiu

Research Scientist, Research, Breakthrough T1D

Lucio Iannone

Managing Director, T1D Fund